Jab cuts heart attack damage by 60 per cent

April 20, 2011 11:50 pm | Updated 11:50 pm IST

A simple injection administered to patients even 12 hours after a heart attack or stroke could cut down their crippling effects by more than half.

British-based scientists have produced an injectible antibody that reduces by more than 60 percent the physical scarring of the heart and brain after an attack.

Heart attacks and strokes are caused by blood flow being blocked by a clot, starving parts of the body further downstream of oxygen.

But most of the permanent damage is caused later — when circulation is eventually restored — and a “default of nature” which means the body's own defences attack the oxygen starved cells.

This effect, which kicks in around nine to 12 hours after the attack or stroke, causes massive inflammation and more than 80 percent of the permanent damage.

It is this that often leads to death and massive reduction in the quality of life of stroke and heart attack survivors.

Now University of Leicester researchers have come up with an injection which can effectively stop the body attacking the oxygen starved cells.

The team first uncovered a key molecule in the process responsible for the immune attack. After identifying the enzyme — called Mannan Binding Lectin-Associated Serine Protease-2 (MASP-2) — they then developed an antibody to knock it out.

The protein — code—named OMS646 — is so effective that only two injections in the first week are needed to completely neutralise MASP-2 while the heart heals itself.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.